GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review

GlobalData
104 Pages - GLDATA62864
$125.00

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respiratory, immuno-inflammation and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc Key Recent Developments

Apr 26,2017: GSK delivers another quarter of continued progress
Mar 22,2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis
Feb 16,2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms
Feb 08,2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016
Jan 19,2017: Abbas Hussain to leave GSK

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

'

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
GlaxoSmithKline Plc - Key Facts 6
GlaxoSmithKline Plc - Key Employees 7
GlaxoSmithKline Plc - Key Employee Biographies 8
GlaxoSmithKline Plc - Major Products and Services 9
GlaxoSmithKline Plc - Pharmaceutical Pipeline Products Data 10
GlaxoSmithKline Plc, Pipeline Products by Therapy Area 10
GlaxoSmithKline Plc, Pipeline Products by Development Phase 12
GlaxoSmithKline Plc - History 13
GlaxoSmithKline Plc - Company Statement 34
GlaxoSmithKline Plc - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 48
Section 2 – Company Analysis 50
GlaxoSmithKline Plc - Business Description 50
GlaxoSmithKline Plc - Corporate Strategy 51
GlaxoSmithKline Plc - SWOT Analysis 52
SWOT Analysis - Overview 52
GlaxoSmithKline Plc - Strengths 52
GlaxoSmithKline Plc - Weaknesses 53
GlaxoSmithKline Plc - Opportunities 54
GlaxoSmithKline Plc - Threats 55
GlaxoSmithKline Plc - Key Competitors 56
Section 3 – Company Financial Ratios 57
Financial Ratios - Capital Market Ratios 57
Financial Ratios - Annual Ratios 58
Performance Chart 61
Financial Performance 61
Financial Ratios - Interim Ratios 62
Financial Ratios - Ratio Charts 63
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances 64
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 64
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 65
GlaxoSmithKline Plc, Recent Deals Summary 66
Section 5 – Company’s Recent Developments 67
Apr 26, 2017: GSK delivers another quarter of continued progress 67
Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 70
Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 72
Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 73
Jan 19, 2017: Abbas Hussain to leave GSK 89
Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 90
Dec 19, 2016: GSK announces Board changes 91
Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 92
Oct 06, 2016: CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration 98
Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare 99
Section 6 – Appendix 100
Methodology 100
Ratio Definitions 100
About GlobalData 104
Contact Us 104
Disclaimer 104

List of Tables
GlaxoSmithKline Plc, Key Facts 6
GlaxoSmithKline Plc, Key Employees 7
GlaxoSmithKline Plc, Key Employee Biographies 8
GlaxoSmithKline Plc, Major Products and Services 9
GlaxoSmithKline Plc, Number of Pipeline Products by Therapy Area 10
GlaxoSmithKline Plc, Number of Pipeline Products by Therapy Area (Cont...1) 11
GlaxoSmithKline Plc, Number of Pipeline Products by Development Stage 12
GlaxoSmithKline Plc, History 13
GlaxoSmithKline Plc, Other Locations 36
GlaxoSmithKline Plc, Subsidiaries 36
GlaxoSmithKline Plc, Joint Venture 48
GlaxoSmithKline Plc, Key Competitors 56
GlaxoSmithKline Plc, Ratios based on current share price 57
GlaxoSmithKline Plc, Annual Ratios 58
GlaxoSmithKline Plc, Annual Ratios (Cont...1) 59
GlaxoSmithKline Plc, Annual Ratios (Cont...2) 60
GlaxoSmithKline Plc, Interim Ratios 62
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 64
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 65
GlaxoSmithKline Plc, Recent Deals Summary 66
Currency Codes 100
Capital Market Ratios 100
Equity Ratios 101
Profitability Ratios 101
Cost Ratios 102
Liquidity Ratios 102
Leverage Ratios 103
Efficiency Ratios 103

List of Figures
GlaxoSmithKline Plc, Pipeline Products by Therapy Area 10
GlaxoSmithKline Plc, Pipeline Products by Development Phase 12
GlaxoSmithKline Plc, Performance Chart (2012 - 2016) 61
GlaxoSmithKline Plc, Ratio Charts 63
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 64
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 65

$125.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838